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Objective. To describe the technique of diaphragmatic peritonectomy (DP) for ovarian cancer cytoreduction and to assess associated morbidity.
Methods. Retrospective review yielded 56 patients who underwent DP as part of a cytoreductive procedure for primary or recurrent ovarian
cancer between 1988 and 2004. Patients who underwent diaphragmatic resection, removal of diaphragmatic implants with CUSA, cautery, curette,
or finger fracture, and patients with pseudomyxoma were excluded from analysis.
Results. DP was performed as a component of primary or secondary cytoreduction in 37 (66%) and 19 (34%) patients, respectively. Extended
procedures including bowel resection, hepatic resection, splenectomy, or radical hysterectomy were performed with DP in 47 patients (82%).
Resection of all diseaseN1 cm was achieved in 95% (microscopic residuum in 43%). For those undergoing primary cytoreduction, median
survival was 59 months and 5-year survival was 49% with median follow-up of 34 months. When performed for recurrent ovarian carcinoma, 5-
year survival was 16% and median survival was 23 months. No intra-operative complications could be specifically attributed to DP. Post-operative
complications included a 30% rate of pleural effusion which was associated with entry into the pleural space during DP (pb0.0001); thoracentesis
was required in 12.5%.
Conclusions. Diaphragmatic metastases are a common obstacle to optimal cytoreduction for patients with ovarian cancer. When necessary,
utilizing DP in concert with other extended procedures to obtain maximal cytoreduction is associated with excellent survival. It should be
recognized that DP is associated with an increased incidence of post-operative pleural effusion, particularly when the pleural space is entered.
© 2008 Elsevier Inc. All rights reserved.Keywords: Ovarian carcinoma; Diaphragm; Cytoreductive surgeryIntroduction
Over the past decade the importance of optimal surgical
cytoreduction prior to administration of cytotoxic chemother-
apy has been more firmly established in the gynecologic
oncology literature [1–5]. The significance of complete, as
opposed to optimal, cytoreduction has also been appreciated [6].
Multiple authors have reported five-year survival rates between
40 and 50% for patients with microscopic residual disease [1,6].
The rate of complete cytoreduction and associated survival has
been shown to be both surgeon and institution dependent [7,8].
The radicality of procedures necessary to obtain this state of⁎ Corresponding author. 200 1st Street NW, Rochester, MN 55905, USA. Fax:
+1 507 266 9300.
E-mail address: dowdy.sean@mayo.edu (S.C. Dowdy).
0090-8258/$ - see front matter © 2008 Elsevier Inc. All rights reserved.
doi:10.1016/j.ygyno.2008.02.012residuum does not appear to influence outcomes [1,5,9].
Although the concept of neoadjuvant chemotherapy has been
championed in some American institutions [10] and in many
centers in Europe [11], this practice is not currently considered
standard of care for women able to tolerate surgical resection.
Recently, Bristow and Chi reported a median reduction in
survival of over 4 months for each cycle of pre-operative
chemotherapy [12]. Thus, any improvement in post-operative
morbidity afforded by neoadjuvant chemotherapy may be more
than offset by a resultant diminution in oncologic outcomes.
These realizations necessitate the widespread adoption of
surgical techniques that enable the surgeon to extirpate disease
present not only within the pelvis, but in the upper abdomen.
Thus, hepatic resection [13], splenectomy [14–16], rectosig-
moid resection [17], video-assisted thoracic surgery (VATS)
[18,19], and diaphragmatic resection [9,20–23] have been
Fig. 2. Right hemidiaphragm following peritoneal stripping. The diaphragmatic
musculature is seen after total resection of peritoneal disease.
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necessary. However, it must be acknowledged that these
interventions come with a potential price of increased post-
operative morbidity. The purpose of this investigation was to
describe the technique of diaphragmatic peritonectomy (DP), in
contrast to diaphragmatic resection, and to explore potential
complications unique to this procedure. This will allow readers
to successfully adopt this procedure into their common practice
and anticipate potential complications.
Patients and methods
From 1988 to 2004, 56 patients who underwent peritoneal stripping of the
diaphragm as part of a primary or secondary cytoreduction were identified from
retrospective chart review. Patients who underwent diaphragmatic resection are
excluded from this analysis and have been reported previously [20]. Entry into
the pleural space without the need for diaphragm resection was not a reason for
exclusion. In these cases the diaphragm was repaired after evacuation of the
pneumothorax without the need for a chest tube. Removal of diaphragmatic
implants using CUSA, cautery, curette, or finger fracture, and patients with
pseudomyxoma were excluded from this analysis.
All operations were performed by a gynecologic oncologist. The decision to
perform DP was dependent on the operating surgeon, the extent of disease found
at laparotomy, and the condition of the patient. It has been our general practice
not to perform extensive or radical procedures unless they are likely to result in
an optimal cytoreduction or improve disease symptoms.
DP is performed only after the upper abdomen has been adequately exposed
and the liver mobilized. Our technique is similar to that previously described for
diaphragmatic resection, and we only briefly review it here [20]. A generous
midline incision is extended to the level of the xiphoid process and the falciform
ligament divided and incised down to the level of the hepatic veins. At this point
the costal angle may be retracted cephalad using any number of retractors; we
prefer to use a fixed third arm. Incision of the coronary ligament of the liver is
extended to the right triangular ligament, allowing the liver to be rotated
medially and inferiorly, exposing the entire diaphragm. Adequate liver
mobilization is crucial, both to gain access to the diseased area, and to avoid
repeated slippage of retractors along the surface of a fixed liver. This may result
in a subcapsular hematoma. The right adrenal gland must also be avoided,
located beneath the bare area of the liver. After the diseased area has been
defined, the peritoneum is incised with a wide margin and reflected from the
underlying musculature of the diaphragm (Figs. 1 and 2). This can be facilitated
with the use of DeMartel clamps and sponge sticks. If significant diaphragmatic
invasion is encountered, diaphragmatic resection is necessary. Otherwise,
reflection of the peritoneum is continued posteriorly until the level of the
coronary ligament incision is reached and the specimen removed.Fig. 1. Gross aspect of metastatic ovarian carcinoma to right hemidiaphragm. A
Mayo–Brown retractor elevates the right costal margin over the cut edge of the
diaphragmatic peritoneum. The liver has been mobilized and retracted medially.Follow-up of patients was performed using information reported in clinical
histories. When information about survival and recurrence was not sufficiently
detailed in the histories, death certificates were obtained and letters to patients
and family physicians or telephone calls were used to obtain follow-up
information. We considered as censored all patients who were alive (with or
without disease) at the time of follow-up or who died of a cause not related to the
disease; patients who died of disease were considered uncensored.
Statistical analyses were performed with Fisher's exact tests to evaluate the
relationship between pairs of categorical variables. Mann–Whitney U test was
used to test for differences between groups in the distributions of continuous
measures. Survival curves were determined by the Kaplan–Meier product-limit
method. Analyses of predictors of disease-related survival (DRS) were
performed using log-rank test. Differences between groups were considered
statistically significant at p≤0.05. JMP statistical program (version 4.0.4, SAS
Institute, Inc., Cray, North Carolina) was used for the analysis. This
investigation was approved by the Institutional Review Board of Mayo
Foundation. In accordance with the Minnesota Statute for Use of Medical
Information in Research, only those patients who consented to the use of their
medical records were included in this analysis.
Results
Patient characteristics are shown in Table 1. Most patients
had high grade, stage IIIC disease and underwent DP as part of a
primary cytoreductive procedure for ovarian carcinoma. The
majority of the procedures were performed only on the right
hemidiaphragm, consistent with the known circulation of
peritoneal fluids along the right colic gutter [4]. As recorded
in Table 2, 82% of patients underwent extended procedures in
addition to diaphragmatic resection, resulting in 95% of patients
in this cohort having an optimal cytoreduction (43% with
microscopic residual, 52% with macroscopic disease measuring
less than 1 cm). All three patients with residual disease greater
than 1 cm died from disease within 12 months.
Post-operative complications occurred in 16 patients and are
listed in Table 3. The most common complication, pleural
effusion, developed in 12 of 40 patients with available post-
operative chest films (30%). Thoracentesis or placement of a
chest tube was required in 5 patients (12.5%) with pleural
effusions; the remaining effusions resolved with conservative
management or were asymptomatic. For the purposes of
comparison, we determined the incidence of post-operative
thoracentesis in our ovarian cancer patients who did not
Table 3
Complications following diaphragmatic peritonectomy
Complication N %
Pleural effusion⁎ 12 30
Ileus 2 4
Pancreatitis 2 4
MI 1 2
Pelvic abscess 1 2
DVT 1 2
Intra-operative atrial fibrillation 1 2
⁎5 patients (12.5%) required thoracentesis or chest tube placement.
Table 1
Patient characteristics
Characteristic N % Median Range
Age 56 21–77
Primary cytoreduction 37 66
Secondary cytoreduction 19 34
Tumor grade
1/2 2 4
3/4 54 96
Stage
IIIC 50 89
IV 6 10
Histological subtype
Serous 47 84
Endometrioid 4 7
Clear cell 3 5
MMMT 1 2
Immature teratoma 1 2
Side of diaphragmatic stripping
Right 46 82
Bilateral 9 16
Left 1 2
Optimal cytoreduction⁎ 53 95
Suboptimal cytoreduction 3 5
⁎Defined here as resection of all tumor nodules measuring greater than 1 cm.
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Thoracentesis in the peri-operative period was necessary in only
2 of 287 patients with stage IIIC disease and carcinomatosis
(0.7%) and in 4 of 95 patients with documented stage IV disease
(4.2%).
Interestingly, the only predictor for the development of post-
operative pleural effusions was entry into the pleural space at
the time of DP (pb0.0001). In fact, entry into the pleural space
occurred in all 5 patients requiring thoracentesis. For the 16
patients in whom the pleural space was entered, 10 (63%)
developed an effusion; 5 patients (31%) required thoracentesis.
In contrast only 2 of 40 patients (5%) in whom the pleural space
was not entered developed effusions and none required
thoracentesis.
In regards to the remaining complications, the patients with
pancreatitis and ileus recovered completely with conservativeTable 2
Extended procedures performed together with diaphragmatic peritonectomy
Procedure N %
Large bowel resection 29 52
Splenectomy 12 21
Small bowel resection 11 19
Radical hysterectomy 11 19
Liver resection 4 7
Inguinal lymphadenectomy 1 2
Total patients undergoing extended procedures
other than diaphragmatic peritonectomy
46 82
Note. percentages are not additive as multiple procedures were performed on
some patients.management. The patient who suffered a myocardial infarction
post-operatively recovered fully. The pelvic abscess resolved
after drainage under CT guidance and treatment with anti-
biotics. An additional patient underwent successful intra-
operative cardioversion for unstable atrial fibrillation. Intra- or
post-operative blood transfusion was necessary in 64% of
patients; a median of 2 U of blood were transfused. Given the
high percentage of extended procedures required for cytoreduc-
tion in this cohort (82%), it is not possible to determine the
blood loss attributable specifically to DP.
Given the absence of a control group, the significance of
survival data in this investigation is of questionable value.
However, K–M survival data for patients following cytoreduc-
tion for primary ovarian cancer is presented in Fig. 3. Median
survival was 59 months and 5-year survival was 49% over a
median follow-up of 34 months. For those patients who
underwent DP for recurrent disease, 5-year survival was 16%
and median survival was an additional 23 months from the time
of secondary cytoreduction. Differences in overall survival
between those with primary and recurrent disease were of
borderline significance (p=0.07).
As we have accumulated more experience with this
technique and anecdotally noted acceptable morbidity, the use
of DP has been utilized at our institution more frequently in
recent years. DP was performed in 23 patients in the five-year
period between 2000 and 2004 as compared to 30 patients
between 1995 and 1999, a 30% increase. This procedure also
occurred more commonly at primary cytoreductive procedures:Fig. 3. Kaplan–Meier survival following diaphragmatic peritonectomy for
patients with primary ovarian cancer.
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setting vs. 57% between 1995 and 1999. In a recent internal
quality assessment of ovarian cancer surgery at our institution,
we noted an increase in the utilization of all diaphragmatic
procedures at primary surgery from 23% of cases with
diaphragm involvement in the period between 1994 and 1998
to 59% in 2006 (unpublished, internal data) [24].
Discussion
The clear association between optimal cytoreduction and
improved survival in patients with advanced ovarian cancer has
resulted in the adoption of techniques to address upper
abdominal disease in many centers [25]. We and others have
provided evidence that survival benefits are not compromised
when radical procedures, including diaphragm resection, are
necessary to achieve optimal cytoreduction [1,21,26]. In a
survey of the SGO, 76% of members polled stated that
diaphragmatic disease was a barrier to optimal cytoreduction
[27]. In the current investigation we analyzed data from
patients who underwent DP, excluding from analysis those
patients who underwent diaphragmatic resection, in order to
describe the technique and identify unique complications or
signs of potential patient compromise. The cohort of patients
undergoing diaphragmatic resection has been analyzed pre-
viously [20].
As described here, DP is a relatively simple procedure and
greatly facilitated by hepatic mobilization. No intra-operative
complications were attributed to DP. Even when performed in
concert with other extended procedures (82% in this study) DP
was well-tolerated. The one exception to this is the relatively
high incidence of post-operative pleural effusions, 30% in our
series. While difficult to compare without a proper control
group, patients having DP required thoracentesis at a rate
significantly higher than that of historical controls at our
institution that underwent surgical cytoreduction without
diaphragmatic surgery (12.5% vs. 0.7 and 4.2% for stage IIIC
with carcinomatosis and stage IV, respectively). In the only
other report of DP which included such information, Eisenhauer
reported an ipsilateral effusion rate of 60% among 40 patients
without pre-operative effusion [28]. However, this series of 59
patients included both diaphragmatic resection and DP. Post-
operative thoracentesis or chest tube placement was required in
15% of patients. This rate of intervention is similar to our
observed rate of 12.5%. Comparison of this rate is more
legitimate recognizing that the overall rate of pleural effusions
(including asymptomatic effusions) will be dependent on the
threshold of the surgical service for obtaining chest films in the
post-operative period.
Using multivariate analysis, Eisenhauer et al. found that only
hepatic mobilization was a statistically significant predictor of
pleural effusions. Since we routinely divide the hepatic
ligaments in order to mobilize the liver, we were unable to
test this association in our cohort. We feel that hepatic
mobilization is critical to attain adequate exposure and to
perform a safe and complete resection, and outweighs a
potential increase in the rate of pleural effusions. Furthermore,this association is likely to be spurious given that all our patients
had liver mobilization, but the rate of thoracentesis was nearly
identical to that reported by Eisenhauer et al. In contrast, we
found a very strong association between diaphragmatic
perforation and post-operative pleural effusion (pb0.0001).
When the pleural space was entered, 63% developed an effusion
and 31% required thoracentesis. Although we routinely check
the diaphragm for air leaks after repair, it may be that with
continued respiration ascites are drawn into the pleural space,
resulting in an effusion in the post-operative period.
Although we concur with Eisenhauer et al. that the relatively
low rate of requirement for thoracentesis does not support the
routine use of prophylactic interventions such as chest tube
placement, the respiratory status of patients with diaphragmatic
perforation at the time of DP should be observed carefully in the
post-operative period. Otherwise, the rate and type of
complications observed was consistent with that seen after
aggressive cytoreduction without DP. We currently utilize this
procedure at more than twice the rate of a decade ago for
patients with primary ovarian cancer, and as noted in other
practices have witnessed a resultant increase in optimal
cytoreduction rates [25].
While the purpose of this investigation was to describe the
technique of DP and evaluate associated complications, we also
note that survival for these patients was excellent. For patients
with primary ovarian cancer, the 5-year survival was 49%. We
have shown previously that in patients with diaphragmatic
disease, diaphragmatic resection or peritonectomy was asso-
ciated with improved survival, even when the analysis was
limited to those patients optimally cytoreduced (55 vs. 28% 5-
year survival, pb0.001) [21]. In this report three patients
underwent DP yet were left with a suboptimal cytoreduction. It
is not our general practice to perform extended procedures such
as DP in the context of a suboptimal cytoreduction. Rarely,
however, initial assessment of cytoreducibility is incorrect.
In summary, DP is a relatively straightforward procedure that
should be a part of the skill set of any surgeon performing
surgical cytoreduction for patients with ovarian cancer.
Adoption of this technique has the potential to improve
maximal cytoreduction rates and patient outcomes. It should
be noted that these patients appear to be more prone to the
development of post-operative pleural effusions. While no
prophylactic intervention is necessary, due vigilance is required
to assess these patients for shortness of breath and the possible
need for thoracentesis.
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